H.C. Wainwright Reiterates Buy Rating on Sanara MedTech (SMTI)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $36.00 price target on Sanara MedTech (NASDAQ: SMTI).

The analyst commented: "Sanara MedTech recently reported its 2025 financial results. For 4Q25, net revenue was $27.5M, representing 4.7% YoY growth (or 13% growth excluding $1.8M BIASURGE sales in 4Q24). Net loss was $1.1M, or ($0.13) per share. For full-year 2025, net revenue was $103.1M, representing 19% YoY growth (or 22% growth excluding $1.8M BIASURGE sales in 4Q24). Net loss was $0.4M, or ($0.05) per share. At the end of December 2025, the company had $16.6M in cash and $46.0M in long-term debt. Cash flows from operating activities were $6.8M during FY2025. Of note, the company is now a pure play surgical business. Management expects FY2026 net revenue to be the in the range of $116-121M, representing 13-17% YoY growth. Specifically, 1Q26 revenue is expected to be in the range of $26.7-27.2M, representing 14-16% YoY growth. The company plans to invest in its field sales team and R&D initiatives to lay the foundation for strong and sustainable growth in 2026 and the coming years. We believe the company could demonstrate both top- and bottom-line growth in 2026. We reiterate our Buy rating and $36 PT."

For an analyst ratings summary and ratings history on Sanara MedTech click here. For more ratings news on Sanara MedTech click here.

Shares of Sanara MedTech closed at $17.24 yesterday.

You May Also Be Interested In

• Waymo Explores Split With Uber - FT
• Jennifer Hyman to retire from Estee Lauder board in November
• McGraw Hill (MH) files for 165M share offering by selling stockholders